Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Hemostemix Inc HMTXF


Primary Symbol: V.HEM

Hemostemix Inc. is a Canada-based autologous stem cell therapy company. The Company has developed, patented, and is scaling a patient’s blood-based stem cell therapeutics platform, which includes angiogenic cell precursors, neuronal cell precursors and cardiomyocyte cell precursors. The Company holds 87 patents on the derivation of three stem cell lineages from the patient’s blood, including... see more

TSXV:HEM - Post Discussion

Hemostemix Inc > Can we hold the line until PP is complete?
View:
Post by JocetooBad on Feb 17, 2023 9:51am

Can we hold the line until PP is complete?

Hey folks, I was able to, sadly, acquire a small number of HEM shares at 20 cents this morning. Would be nice that we really to hold the line above 20 cents at least until this PP is closed. It'll hurt if we can't close it this time, IMO. Timing is critical now.
Be the first to comment on this post
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities